What's Happening?
Jane Koo, PhD, head of regulatory at CTMC, is spearheading regulatory strategies to accelerate the development and industrialization of innovative cell and gene therapies. With 20 years of experience in biologics and advanced therapies, Koo specializes in translating complex technical data into actionable strategies, focusing on monoclonal antibodies and cell-based therapies. Her efforts aim to transform treatment options and advance the fight against cancer, leveraging her track record of securing first-to-market approvals.
Why It's Important?
Koo's leadership in regulatory strategies is crucial for the advancement of cell and gene therapies, which hold the potential to revolutionize cancer treatment and other medical fields. By navigating complex regulatory landscapes, she ensures that innovative therapies reach the market efficiently, potentially improving patient access to cutting-edge treatments. Her work supports the growth of the biotech industry, fostering innovation and competitiveness in the U.S. healthcare sector.
